According to FutureWise analysis the market for anti-cathepsin b in 2023 is US$ 0.18 billion, and is expected to reach US$ 0.23 billion by 2031 at a CAGR of 3%.
Cathepsin B, also known as Cathepsin B1, RSG-2, is a family of lysosomal cysteine proteases encoded by the CTSB gene. Cathepsin B is synthesized as a pro cathepsin with a signal peptide of 17 AA (amino acids) that directs it to the lumen of the rough ER (endoplasmic reticulum), where the signal peptide is removed to generate the inactive pro cathepsin B with a propeptide sequence. Anti-cathepsin B antibodies immunize the protein encoded by the CTSB gene. In humans, the canonical protein has a reported length of 339 amino acid residues and a mass of 37.8 kDa. Its subcellular localization is in the lysosomes and cell membrane. It is said to be expressed in the stratum spinosum of the epidermis. A part of the Peptidase C1 protein family, it is reported to be a thiol protease, which participates in intracellular degradation and renewal of proteins.
Anti-cathepsin B is most commonly used to treat cancers, ebola infections, traumatic brain injuries, and fertility issues. The rise in the incidence rate of cancer is the leading cause of death globally. Cathepsin B is usually associated with the lysosomes in autophagy and immune response, but its anomalous expression has been shown to lead to cancers. The proteolytic nature of cathepsin B has been attributed to the infiltrative nature of tumor cells, and it has been shown that cathepsin B is secreted into the extracellular matrix (ECM), thereby facilitating its destruction. Overexpression of cathepsin B has been observed in various malignancies, including brain, lung, prostate, breast, and colorectal cancer. The altered regulation of cathepsin B can occur at various levels.
FutureWise Market Research has published a report that provides an insightful analysis anti-cathepsin B market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, anti-cathepsin B market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.